October 12, 2020 Comments Off on Cytobyte Inc. Securities Investigation Blog, Current Investigations

Cytobyte Inc. Securities Investigation

Cytobyte Inc. Securities Investigation, featured by top securities fraud attorneys, the White Law Group

Concerned about your investment in Cytobyte, Inc.? 

Are you concerned about your investment in Cytobyte, Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

The company, based in Cleveland, Ohio,  filed a form D to raise capital from investors in 2016. The total offering amount was purportedly $1,806,000, according to the Reg D.

Filing a Complaint against your Brokerage Firm

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with pharmaceutical and biotech investments such as  Cytobyte Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Cytobyte, Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

Comments are closed.